• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.

作者信息

Strouse Christopher, Mott Sarah L, Smith Brian J, Magalhaes-Silverman Margarida, Farooq Umar, Zhan Fenghuang, Jethava Yogesh, Tricot Guido

机构信息

Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.

出版信息

Bone Marrow Transplant. 2024 Jan;59(1):128-130. doi: 10.1038/s41409-023-02119-9. Epub 2023 Oct 10.

DOI:10.1038/s41409-023-02119-9
PMID:37816907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10781621/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94f8/10781621/382b2181d27e/41409_2023_2119_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94f8/10781621/382b2181d27e/41409_2023_2119_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94f8/10781621/382b2181d27e/41409_2023_2119_Fig1_HTML.jpg

相似文献

1
Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.硼替佐米、沙利度胺和马法兰进行移植预处理以及对老年多发性骨髓瘤患者进行强化的移植后2年治疗。
Bone Marrow Transplant. 2024 Jan;59(1):128-130. doi: 10.1038/s41409-023-02119-9. Epub 2023 Oct 10.
2
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.硼替佐米、沙利度胺和地塞米松成功治疗骨髓移植后浆细胞骨髓瘤。
Leuk Lymphoma. 2024 Jul;65(7):1016-1019. doi: 10.1080/10428194.2024.2329322. Epub 2024 Apr 1.
3
Tandem transplants in the treatment of multiple myeloma. Pro.串联移植治疗多发性骨髓瘤。专业人士。 （你提供的原文似乎不太完整，翻译可能不太准确，建议补充完整原文以便更精准翻译）
Clin Adv Hematol Oncol. 2004 May;2(5):303-4.
4
Treatment of multiple myeloma: 2009 update.多发性骨髓瘤的治疗：2009年更新
Prescrire Int. 2009 Dec;18(104):263-6.
5
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.硼替佐米为基础的治疗方案在不适合自体造血干细胞移植的初诊多发性骨髓瘤患者中的应用：捷克注册研究数据。
Eur J Haematol. 2021 Oct;107(4):466-474. doi: 10.1111/ejh.13683. Epub 2021 Jul 28.
6
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.硼替佐米联合来那度胺与烷化剂和皮质类固醇在多发性骨髓瘤一线治疗中的临床疗效和成本效益：系统评价和经济评估。
Health Technol Assess. 2011 Dec;15(41):1-204. doi: 10.3310/hta15410.
7
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.序贯长春新碱、阿霉素、地塞米松（VAD）方案联合硼替佐米、沙利度胺、地塞米松（VTD）方案诱导，大剂量化疗联合自体造血干细胞移植巩固治疗初治多发性骨髓瘤的Ⅱ期临床研究。
Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.
8
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.来那度胺和地塞米松与硼替佐米和地塞米松治疗对美法仑耐药的多发性骨髓瘤：一项随机研究。
Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30.
9
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.硼替佐米联合沙利度胺-地塞米松用于既往未经治疗的多发性骨髓瘤
Hematology. 2007 Jun;12(3):235-9. doi: 10.1080/10245330701214236.
10
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.多发性骨髓瘤髓外进展，尽管同时对多种联合疗法和自体移植有髓内反应：一例报告
J Med Case Rep. 2014 Sep 8;8:299. doi: 10.1186/1752-1947-8-299.

本文引用的文献

1
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.卡非佐米、来那度胺和地塞米松或来那度胺单药作为自体造血干细胞移植后多发性骨髓瘤患者的维持治疗（ATLAS）：一项随机、开放标签、3 期临床试验的中期分析。
Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12.
2
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.硼替佐米联合大剂量马法兰预处理方案在一线多发性骨髓瘤中的应用：一项 IFM 随机 3 期研究。
Blood. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635.
3
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.卡非佐米联合环磷酰胺和地塞米松或来那度胺和地塞米松联合自体移植，或卡非佐米联合来那度胺和地塞米松，随后用卡非佐米联合来那度胺或来那度胺维持治疗新诊断的多发性骨髓瘤患者（FORTE）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
4
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.年龄不是障碍：CIBMTR 对接受自体造血细胞移植治疗多发性骨髓瘤的老年患者的分析。
Cancer. 2020 Dec 1;126(23):5077-5087. doi: 10.1002/cncr.33171. Epub 2020 Sep 23.
5
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?大剂量美法仑联合自体造血干细胞移植在多发性骨髓瘤中的作用：是否是时候改变模式了？
Br J Haematol. 2020 Dec;191(5):692-703. doi: 10.1111/bjh.16764. Epub 2020 Jun 5.
6
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.了解多发性骨髓瘤的死亡率：一项欧洲回顾性图表审查的结果。
Eur J Haematol. 2019 Aug;103(2):107-115. doi: 10.1111/ejh.13264. Epub 2019 Jun 18.
7
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma.一项沙利度胺联合硼替佐米和大剂量马法兰作为多发性骨髓瘤患者自体干细胞移植预处理方案的 I/II 期递增剂量研究。
Bone Marrow Transplant. 2019 Nov;54(11):1881-1891. doi: 10.1038/s41409-019-0534-0. Epub 2019 May 17.
8
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.在多发性骨髓瘤自体造血细胞移植前，白消安加美法仑与单用美法仑进行预处理的比较：一项开放标签、随机、3期试验。
Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.
9
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.来那度胺维持治疗与观察用于初诊多发性骨髓瘤患者（Myeloma XI）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.
10
In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study.老年多发性骨髓瘤患者自体造血干细胞移植后的院内死亡率和移植后并发症：一项基于人群的研究
Biol Blood Marrow Transplant. 2017 Jul;23(7):1203-1207. doi: 10.1016/j.bbmt.2017.03.012. Epub 2017 Mar 9.